HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells

INTRODUCTION: Although the mechanistic target of rapamycin (mTOR) might be a promising molecular target to treat advanced bladder cancer, resistance develops under chronic exposure to an mTOR inhibitor (everolimus, temsirolimus). Based on earlier studies, we proposed that histone deacetylase (HDAC)...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Juengel, Eva, Najafi, Ramin, Rutz, Jochen, Maxeiner, Sebastian, Makarevic, Jasmina, Roos, Frederik, Tsaur, Igor, Haferkamp, Axel, Blaheta, Roman A.
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5746361/
https://ncbi.nlm.nih.gov/pubmed/29299126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22454
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares